Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
Status:
RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral antibiotic switch in comparison with standard intravenous antibiotic regime among patients with uncomplicated Staphylococcus aureus bacteraemia (SAB). The study is based on the hypothesis that an early switch from IV to oral antimicrobial therapy is non-inferior and safe compared to conventional minimum 14-day course of IV therapy in patients with low-risk uncomplicated SAB.
Phase:
PHASE3
Details
Lead Sponsor:
Clinical Research Centre, Malaysia
Treatments:
Cefazolin Ceftaroline Clindamycin Cloxacillin Linezolid Trimethoprim, Sulfamethoxazole Drug Combination Vancomycin